<?xml version="1.0" encoding="UTF-8"?>
<p id="Par74">So, 
 <bold>Strengths</bold> of the potential market of medical cannabis in Ukraine are as follows: 
 <list list-type="order">
  <list-item>
   <p id="Par75">The considerable growth of research articles devoted to use of cannabis and cannabinoids in medical practice: by the end of January 2020, 21.459 papers were published on PubMed, 15.391 of them concerned the influence of cannabis on a human body. During the last 5â€‰years, articles growth on the topic constituted 105%. Besides, the report of the American National Academy of Sciences, the Health Canada review, etc. are accessible, so a considerable experience of medical use of cannabis is obtained (PubMed 
    <xref ref-type="bibr" rid="CR36">2020</xref>; Usenko and Kosyachenko 
    <xref ref-type="bibr" rid="CR54">2019</xref>).
   </p>
  </list-item>
  <list-item>
   <p id="Par76">The presence of the potential participants for this market in Ukraine: domestic and foreign pharmaceutical manufacturers, agriculture companies, analytical laboratories, higher educational establishments, scientific research institutions, pharmacies, in particular those having licenses for extemporaneous compounding, wholesale pharmaceutical companies, etc.</p>
  </list-item>
  <list-item>
   <p id="Par77">The current legal and regulatory framework does not require considerable changes. Basically, corrections and amendments are needed to be in line with the international conventions requirements. The positive factor is also liberalization of the national legislation on the circulation of narcotic and psychotropic drugs, aimed at the improvement of their physical and economic availability for patients, in the palliative medicine sphere in particular.</p>
  </list-item>
  <list-item>
   <p id="Par78">The presence of state regulatory bodies which can function as the Cannabis Agency in accordance with the requirements of Art. 23 and Art. 28 of the 1961 Convention (United Nations 
    <xref ref-type="bibr" rid="CR51">1961</xref>), and also of the Monitoring center to gain information on narcotic and psychotropic drugs consumption to assess the needs and quota limits.
   </p>
  </list-item>
  <list-item>
   <p id="Par79">The presence of qualified personnel (specialists of pharmaceutical and agriculture businesses, scientists, teachers, physicians, pharmacists, Health Technology Assessment (HTA) professionals, representatives of state regulatory bodies, etc.) who can practically apply the obtained knowledge and skills in the public health sphere, business, science, education, regulation sphere and so on.</p>
  </list-item>
 </list>
</p>
